Promising results for the ultra-low risk patient group in latest MINDACT analysis

On January 27, 2022 EORTC reported The MINDACT (EORTC 10041/BIG3-04) study, a multicentre, randomised phase 3 clinical trial, aims to identify those women with early-stage breast cancer who can be spared chemotherapy after surgery through the use of a genomic and clinical risk assessment. Between 2007 and 2011, 6693 patients aged 18 to 70 whose cancer had either not spread to the lymph nodes under the arm, or to no more than three nodes, were enrolled to the trial, which was carried out in 112 institutions in nine European countries (Press release, EORTC, JAN 27, 2022, View Source [SID1234607424]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The latest sub-group analysis, published recently in the Journal of Clinical Oncology* looked at the 15% of patients who had an ultra-low genomic risk of recurrence based on the 70-gene signature MammaPrint. After a median follow-up of 8.7 years, 99% of these patients had not died from their disease, and their risk of cancer spreading to other parts of the body (distant metastasis) was significantly less than for patients with low-risk tumours. Patients with ultra-low risk tumours had an excellent prognosis regardless of the result of their clinical risk assessment.

Of the ultralow-risk patients, 67% were aged 50 years or more, and 99% were estrogen receptor (ER)-positive. Systemic therapy was received by 84% of patients (69% endocrine therapy (ET), 14% endocrine therapy plus chemotherapy, 1% other) and 16% received no adjuvant systemic treatment.

"Although trials have shown that gene signatures can be used to identify subgroups of patients who can safely be spared chemotherapy, current guidelines still include the use of ET in all hormone receptor positive patients, even those at very low risk" said Dr Josephine Lopes Cardozo, from the Netherlands Cancer Institute and EORTC. "ET side effects are often underestimated, and, as a result, adherence to the treatment is poor, with only half of all patients finishing a five-year course. Our analysis of ultra-low risk patients shows that these patients might be candidates for further reduction of treatments such as ET."

The investigators hope that the ultra-low risk gene signature will be used in future trials investigating the de-escalation of ET in order to achieve a better balance between benefit and harm. Findings from earlier studies have suggested that the introduction of population-based screening programmes has led to an increase of tumours with low-risk and ultra-low risk molecular profiles, and that these are over-represented within screen-detected cancers. "Being able to identify these patients who may have a limited benefit from ET could help to personalize treatment by reducing treatment durations or completely omitting ET and ultimately preventing overtreatment," says Dr Lopes Cardozo. "This would have benefits not only for patients, but also save money for healthcare systems."

Chimeric Therapeutics secures US patent for CLTX CAR technology key to advancing pipeline

On January 27, 2022 Chimeric Therapeutics Ltd (ASX:CHM) reported that it has been issued a patent from the Unites States Patent and Trademark Office covering certain applications of chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX), including Chimeric’s clinical-stage CAR T asset CHM 1101 and preclinical-stage CAR NK asset CHM 1301 (Press release, Chimeric Therapeutics, JAN 27, 2022, https://chimerictherapeutics.com/wp-content/uploads/2022/01/CHM-Receives-US-Patent-covering-CLTX-CAT-Technology.pdf [SID1234607406]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patent has been granted under patent number US 11,230,577 B2 and entitled ‘Chimeric antigen receptors containing a chlorotoxin domain’.

Chimeric Therapeutics holds the exclusive worldwide licence to develop and commercialise US 11,230,577 B2 and related patent applications filed in other global territories.

Continued IP portfolio momentum
Chimeric Therapeutics CEO and managing director Jennifer Chow said: "We are delighted to have patent protection granted for CLTX CAR therapies in the United States, the single largest global market for biopharmaceutical products.

"The granting of this key US patent continues the momentum for the intellectual property portfolio underpinning our CLTX CAR pipeline assets, following the recent patent grant in Europe in September."

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed by scientists at the City of Hope Medical Centre in California for the treatment of patients with solid tumours.It is currently being studied in a phase 1 clinical trial in recurrent/ progressive glioblastoma.

A second CLTX CAR T phase 1 clinical trial is planned to begin in 2022 in additional solid tumours.

CHM 2101 (CDH17 CAR T) is a novel, third-generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 is in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.

First Patient Enrolled in Phase I Clinical Trial for Boan Biotech’s Investigational Anti-Claudin 18.2 Antibody Drug BA1105

On January 26, 2022 Luye Pharma Group reported that the first patient has been enrolled in a Phase I clinical trial for BA1105, an investigational anti-Claudin18.2 antibody developed by its subsidiary Boan Biotech (Press release, Luye Pharma, JAN 26, 2022, View Source [SID1234638771]). The Phase I clinical trial is designed to evaluate the safety, tolerance and pharmacokinetics of BA1105 in patients with advanced solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BA1105 is a recombinant human anti-Claudin18.2 IgG1 monoclonal antibody for treating Claudin18.2-positive advanced solid tumors. Claudin18.2 is a potential target for treating gastrointestinal tumors. It is consistently and highly expressed in gastrointestinal tumors. Research shows that 70% of gastric cancer patients, 50% of pancreatic cancer patients and 30% of esophageal cancer patients are Claudin18.2 positive.

The incidence of gastrointestinal tumors in China is very high, and there are many unmet needs of patients to be addressed. According to data from the International Agency for Research on Cancer (IARC), gastric cancer, esophageal cancer, and pancreatic cancer are among the 10 most common malignant cancers in China, with the number of new cases in 2020 being approximately 480,000, 320,000, and 120,000, respectively1. More than 40% of the new gastric cancer cases worldwide are in China. Due to the lack of early diagnosis, most gastric cancer patients are diagnosed at an advanced stage. There are limited therapy options for advanced gastric cancer and more effective therapies are needed to improve patient survival. Antibodies targeting Claudin18.2 are promising drugs against gastrointestinal tumors.

Unlike the common ADCC-enhancing technique that decreases the antibody’s fucose level through cell engineering, BA1105 enhances ADCC by inducing amino acid mutations in the Fc region. These mutations increase BA1105’s affinity to the agonistic Fc receptor without altering its affinity to the inhibitory receptor CD32b, to prevent the drug’s antitumor activity from being inhibited by the inhibitory receptor.

An in vivo efficacy study for BA1105 showed that it demonstrated a high antitumor activity in tumor models with low or high Claudin 18.2 levels either alone or in combination with chemotherapeutic agents. In vitro efficacy studies showed that BA1105 was 10-fold more potent than the reference antibody against cancer cells with either low or high Claudin 18.2 levels. BA1105 is expected to become the best-in-class targeted therapy for certain cancers such as the metastatic pancreatic cancer, the advanced gastric cancer, and the gastro-esophageal junction (GEJ) adenocarcinoma.

Boan Biotech has been building a diversified product portfolio focusing on innovative biologics. In addition to BA1105, the company’s R&D pipeline also includes more than 10 other proprietary innovative antibody candidates and various biosimilar candidates, and some of them are undergoing clinical trials in the United States, Europe, China, and other countries and regions around the world. The company is accelerating its global development, and is committed to serving patients around the world with high-quality biopharmaceutical products.

Defence’s AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

On January 26,2022 Defence Therapeutics Inc. ("Defence" or the "Company"), a pre-clinical biotechnology company developing various immune-oncology products, is pleased to reported the development of AccuVAC-PT009, a new protein-based HPV vaccine, leading to a humoral response bypassing Gardasil-9 (Merck) immunogenicity in animals (Press release, Defence Therapeutics, JAN 26, 2022, View Source [SID1234626246]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ACCUMTM is a platform technology 100% owned by Defence Therapeutics. ACCUMTM is an enabling technology as it can be used to enhance the intracellular accumulation of various proteins of pharmacological interests into any target cells. As such, it is currently used by Defence for the development of several anti-cancer and COVID vaccines, as well as for the improvement of approved or in development antibody-drug conjugates.

To further demonstrate the ACCUMTM versatility, the Defence research and development team designed and engineered a HPV vaccine (a mix of the same 9 HPV-derived L1 proteins used in Gardasil-9) and compared its immunogenicity to a group of Gardasil-9-immunized animals. Compared to Gardasil-9, AccuVAC-PT009 triggers an impressive 27-and 36-fold increase in antibody titer at 4-and 6-weeks post-immunization respectively.

"We are extremely proud to demonstrate again how ACCUMTM can be exploited and applied to significantly improve any protein-based vaccine. Not only can this vaccine have a tremendous impact on improving the immunogenicity of the commercialized Gardasil-9, but it can in addition lower the dosing regimen (at least by 10-fold) yet triggering similar or more potent humoral response", says Mr. Plouffe, the CEO of Defence.

According to Fortune Business Insights, the global HPV vaccine market size was valued at $3.80 Bn in 2019 & is projected to reach $12.69 Bn by 2027, with a CAGR of 16.3%.

Defence Therapeutics is currently working on various scenarios. Although its initial intent is to pursue the development of its AccuVAC-PT009 HPV vaccine candidate or even adding other subtypes currently not covered by Gardasil-9, the company is actively looking for to establish partnerships with major pharmaceuticals players to bring forward its vaccine portfolio.

Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

On January 26, 2022 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, will provide a clinical update during today’s conference call and webcast at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Company’s website (Press release, Cue Biopharma, JAN 26, 2022, View Source [SID1234608262]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Members of the Cue Biopharma executive management team will provide an update from the Company’s ongoing clinical trials with CUE-101, its lead and representative IL-2 based drug product candidate from the CUE-100 series. CUE-101 is currently in a Phase 1b clinical trial for the treatment of third line and beyond HPV+ recurrent/metastatic head and neck squamous cell carcinoma. The discussion will focus on recent data updates from the Phase 1b monotherapy dose expansion trial and the dose escalation combination trial evaluating CUE-101 front line with Merck’s KEYTRUDA (pembrolizumab). Management will also provide an update on the Company’s pipeline development progress from the IL-2 based CUE-100 series including CUE-102, with an Investigational New Drug (IND) filing planned for the first quarter of 2022, as well as updates on its strategic objectives and anticipated milestones.

Webcast Details

Wednesday, January 26, 2022 at 4:30 p.m. EST
Investors: 877-407-9208
International: 201-493-6784
Conference ID: 13726509
Webcast: View Source;tp_key=7a7d92f501